Zepp Health Soars 3.49% on Q2 Revenue Surge

Zepp Health's stock price surged by 3.49% in pre-market trading on August 6, 2025, indicating a strong start to the day's trading session.

Zepp Health has received a consensus rating of Buy from analysts, with an average rating score of 3.00. This rating is based on one buy rating, with no hold or sell ratings, suggesting a positive outlook for the company's stock.

In the second quarter of 2025, Zepp Health reported a significant revenue surge, driven by the success of its Amazfit products, including the Bip 6 and T-Rex. This growth in revenue has contributed to the company's stock price increase, with shares up 27% from a week ago.

The company's stock has seen a remarkable 336% share price jump in the last month, reflecting strong investor confidence and market performance. This surge has been accompanied by a 36.62% increase in stock price on August 5, 2025, reaching a 52-week high of $23.80.